News
This twice-a-year shot to prevent HIV could stop transmission — if people can get it
The U.S. has approved the world’s only twice-a-year shot to prevent HIV, the first step in an anticipated global rollout that could protect millions – although it’s unclear how many in the U.S. and abroad will get access to the powerful new option.
FDA Approves First Twice-a-Year HIV Prevention Shot
Made by Gilead Sciences and sold under the name Yeztugo, the drug gives people a new way to stay protected from HIV without needing daily pills or frequent injections, The New York Times reported. “We’re on the precipice of now being able to deliver the greatest prevention option we’ve had in 44 years of this epidemic,
Gilead Sciences (NASDAQ:GILD) has demonstrated a strong performance this year, with its stock up 18% compared to the S&P ...
The Food and Drug Administration approved the preventative use of lenacapavir, made by Gilead Sciences, on Wednesday. Experts ...
The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for ...
Gilead's CEO says he's committed to making sure people around the world can get his firm's new HIV prevention shot Yeztugo.
Gilead Sciences garnered investor and analyst focus after the U.S. FDA approval of Yeztugo, or lenacapavir, the company’s ...
IFLScience on MSN17h
Revolutionary Drug That's “Closest Thing” To HIV Vaccine Gets FDA ApprovalThe breakthrough double injection won’t be cheap in the US, although scientists argue it could (and should) be.
Gilead has won FDA approval for an HIV prevention shot that is administered only once every six months. When will low-income ...
With the FDA’s much-anticipated nod for Gilead Sciences’ long-acting HIV pre-exposure prophylaxis (PrEP) injection Yeztugo ...
Zacks Investment Research on MSN1d
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-TermIt doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ...
Gilead is now waiting for regulatory decisions on the twice-yearly PrEP in Europe and other markets, including South Africa ...
A United Nations agency has urged the pharmaceutical company Gilead Sciences to lower the price of the long acting antiviral treatment lenacapavir following the US Food and Drug Administration (FDA)’s ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback